Systemic therapeutic options for carcinoid

Seminars in Oncology

Volumn 40, Issue 1, 2013, Pages 84-99

  Pavel, Marianne ^a   Kidd, Mark ^b   Modlin, Irvin ^b  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOPEPTIN; BEVACIZUMAB; CAPECITABINE; CAPECITABINE PLUS OXALIPLATIN; CISPLATIN; DACARBAZINE; DOXORUBICIN; EDOTREOTIDE; ENDOSTATIN; ETOPOSIDE; EVEROLIMUS; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; OCTREOTIDE; OXALIPLATIN; PASIREOTIDE; PEGINTERFERON; RECOMBINANT ALPHA INTERFERON; RECOMBINANT ALPHA2A INTERFERON; RECOMBINANT ALPHA2B INTERFERON; SOMATOSTATIN DERIVATIVE; SORAFENIB; STREPTOZOCIN; SUNITINIB; TEMOZOLOMIDE; TEMSIROLIMUS; THALIDOMIDE; UNINDEXED DRUG; VATALANIB;

ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; BLOOD TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER GRADING; CANCER GROWTH; CANCER OF UNKNOWN PRIMARY SITE; CANCER REGRESSION; CARCINOID SYNDROME; CHEMOEMBOLIZATION; CYTOREDUCTIVE SURGERY; DRUG EFFICACY; DRUG TREATMENT FAILURE; FATIGUE; G1 PHASE CELL CYCLE CHECKPOINT; GASTROINTESTINAL SYMPTOM; HUMAN; MONOTHERAPY; NEUROENDOCRINE TUMOR; OVERALL SURVIVAL; PANCREATIC NEUROENDOCRINE TUMOR; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SKIN TOXICITY; TREATMENT RESPONSE;

ANTINEOPLASTIC AGENTS; CARCINOID TUMOR; CLINICAL TRIALS AS TOPIC; HUMANS; INTERFERON-ALPHA; OCTREOTIDE; SIROLIMUS; SOMATOSTATIN; TREATMENT OUTCOME;

EID: 84873375319     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.seminoncol.2012.11.003     Document Type: Article

References (107)

1. S. Oberndorfer Karzinoide Tumoren des Dünndarmes Fr Zeitschrift Pathol 1 1907 426 429
2. C. Ciaccio Sur une nouvelle espéce cellulaire dans les glandes de Lieberkühn CR Soc Biol Paris 60 1906 76 77
3. P. Masson La glande endocrine de l'intestin chez l'homme CR Acad Sci 158 1914 59 61
4. E.D. Williams, M. Sandler The classification of carcinoid tumours Lancet 1 1963 238 239
5. F.T. Bosman WHO classification of tumours of the digestive system 4th Ed. 2010 World Health Organization.; International Agency for Research on Cancer Lyon
6. W.D. Travis, E. Brambilla, H. Muller-Hermlink, C. Harris World Health Organization classification of tumours World Health Organization classification of tumours. Pathology and genetics of tumours of the lung, pleura, thymus and heart 2004 IARC Press Lyon
7. I. Modlin, K. Oberg Oberndorfer centennial 2008 Felsenstein CCCP Hannover
8. J.C. Yao, M. Hassan, A. Phan One hundred years after " carcinoid": epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States J Clin Oncol 26 2008 3063 3072
9. B. Lawrence, B.I. Gustafsson, A. Chan, B. Svejda, M. Kidd, I.M. Modlin The epidemiology of gastroenteropancreatic neuroendocrine tumors Endocrinol Metab Clin North Am 40 2011 1 18
10. E.M. Bertino, P.D. Confer, J.E. Colonna, P. Ross, G.A. Otterson Pulmonary neuroendocrine/carcinoid tumors: a review article Cancer 115 2009 4434 4441
11. G. Fink, T. Krelbaum, A. Yellin Pulmonary carcinoid: presentation, diagnosis, and outcome in 142 cases in Israel and review of 640 cases from the literature Chest 119 2001 1647 1651
12. B. Lawrence, B.I. Gustafsson, M. Kidd, I. Modlin New pharmacologic therapies for gastroenteropancreatic neuroendocrine tumors Gastroenterol Clin North Am 39 2010 615 628
13. M.H. Kulke, L.L. Siu, J.E. Tepper Future directions in the treatment of neuroendocrine tumors: consensus report of the National Cancer Institute Neuroendocrine Tumor clinical trials planning meeting J Clin Oncol 29 2011 934 943
14. C. Durante, H. Boukheris, C. Dromain Prognostic factors influencing survival from metastatic (stage IV) gastroenteropancreatic well-differentiated endocrine carcinoma Endocr Relat Cancer 16 2009 585 597
15. F. Panzuto, S. Nasoni, M. Falconi Prognostic factors and survival in endocrine tumor patients: comparison between gastrointestinal and pancreatic localization Endocr Relat Cancer 12 2005 1083 1092
16. M. Pavel, E. Baudin, A. Couvelard ENETS Consensus Guidelines for the management of patients with liver and other distant metastases from neuroendocrine neoplasms of foregut, midgut, hindgut, and unknown primary Neuroendocrinology 95 2012 157 176
17. J. Strosberg, N. Gardner, L. Kvols Survival and prognostic factor analysis of 146 metastatic neuroendocrine tumors of the mid-gut Neuroendocrinology 89 2009 471 476
18. U.F. Pape, U. Berndt, J. Muller-Nordhorn Prognostic factors of long-term outcome in gastroenteropancreatic neuroendocrine tumours Endocr Relat Cancer 15 2008 1083 1097
19. U.F. Pape, H. Jann, J. Muller-Nordhorn Prognostic relevance of a novel TNM classification system for upper gastroenteropancreatic neuroendocrine tumors Cancer 113 2008 256 265
20. S. Reichlin Somatostatin N Engl J Med 309 1983 1495 1501
21. B. Eriksson, G. Kloppel, E. Krenning Consensus guidelines for the management of patients with digestive neuroendocrine tumors - well-differentiated jejunal-ileal tumor/carcinoma Neuroendocrinology 87 2008 8 19
22. J.P. Boudreaux, D.S. Klimstra, M.M. Hassan The NANETS consensus guideline for the diagnosis and management of neuroendocrine tumors: well-differentiated neuroendocrine tumors of the jejunum, ileum, appendix, and cecum Pancreas 39 2010 753 766
23. U. Plockinger, B. Wiedenmann Neuroendocrine tumors Biotherapy Best Pract Res Clin Endocrinol Metab 21 2007 145 162
24. J.C. Reubi, J.C. Schaer, B. Waser, G. Mengod Expression and localization of somatostatin receptor SSTR1, SSTR2, and SSTR3 messenger RNAs in primary human tumors using in situ hybridization Cancer Res 54 1994 3455 3459
25. O. Nilsson, L. Kolby, B. Wangberg Comparative studies on the expression of somatostatin receptor subtypes, outcome of octreotide scintigraphy and response to octreotide treatment in patients with carcinoid tumours Br J Cancer 77 1998 632 637
26. I.M. Modlin, M. Pavel, M. Kidd, B.I. Gustafsson Review article: somatostatin analogues in the treatment of gastroenteropancreatic neuroendocrine (carcinoid) tumours Aliment Pharmacol Ther 31 2010 169 188
27. L.K. Kvols, C.G. Moertel, M.J. O'Connell, A.J. Schutt, J. Rubin, R.G. Hahn Treatment of the malignant carcinoid syndrome Evaluation of a long-Acting somatostatin analogue N Engl J Med 315 1986 663 666
28. P. Ruszniewski, S. Ish-Shalom, M. Wymenga Rapid and sustained relief from the symptoms of carcinoid syndrome: results from an open 6-month study of the 28-day prolonged-release formulation of lanreotide Neuroendocrinology 80 2004 244 251
29. M.K. Chadha, J. Lombardo, T. Mashtare High-dose octreotide acetate for management of gastroenteropancreatic neuroendocrine tumors Anticancer Res 29 2009 4127 4130
30. C. Verslype Dose escalation of octreotide LAR is safe and effective in patients with advanced gastrointestinal neuroendocrine tumours for control of symptoms and tumor progression Acta Gastroenterol Belg 74 2011 93 94
31. S. Faiss, U. Rath, U. Mansmann Ultra-high-dose lanreotide treatment in patients with metastatic neuroendocrine gastroenteropancreatic tumors Digestion 60 1999 469 476
32. C. Susini, L. Buscail Rationale for the use of somatostatin analogs as antitumor agents Ann Oncol 17 2006 1733 1742
33. S. Grozinsky-Glasberg, G. Kaltsas, C. Gur Long-Acting somatostatin analogues are an effective treatment for type 1 gastric carcinoid tumours Eur J Endocrinol 159 2008 475 482
34. A. Rinke, H.H. Muller, C. Schade-Brittinger Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group J Clin Oncol 27 2009 4656 4663
35. M.E. Pavel, J.D. Hainsworth, E. Baudin Everolimus plus octreotide long-Acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study Lancet 378 2011 2005 2012
36. M. Ducreux, P. Ruszniewski, J.A. Chayvialle The antitumoral effect of the long-Acting somatostatin analog lanreotide in neuroendocrine tumors Am J Gastroenterol 95 2000 3276 3281
37. NCCN Clinical Practice Guidelines in Oncology: neuroendocrine tumors. J Natl Compr Cancer Netw. Version 1.2012.
38. D. Campana, F. Nori, R. Pezzilli Gastric endocrine tumors type I: treatment with long-Acting somatostatin analogs Endocr Relat Cancer 15 2008 337 342
39. S. Manfredi, M. Pagenault, A.S. de Lajarte-Thirouard, J.F. Bretagne Type 1 and 2 gastric carcinoid tumors: long-term follow-up of the efficacy of treatment with a slow-release somatostatin analogue Eur J Gastroenterol Hepatol 19 2007 1021 1025
40. P. Tomassetti, M. Migliori, G.C. Caletti, P. Fusaroli, R. Corinaldesi, L. Gullo Treatment of type II gastric carcinoid tumors with somatostatin analogues N Engl J Med 343 2000 551 554
41. C.S. Jianu, R. Fossmark, U. Syversen, O. Hauso, V. Fykse, H.L. Waldum Five-year follow-up of patients treated for 1 year with octreotide long-Acting release for enterochromaffin-like cell carcinoids Scand J Gastroenterol 46 2011 456 463
42. 177Lu-DOTA 0,Tyr3]octreotate: toxicity, efficacy, and survival J Clin Oncol 26 2008 2124 2130
43. 90Y- edotreotide for metastatic carcinoid refractory to octreotide J Clin Oncol 28 2010 1652 1659
44. 90Y-DOTA]-TOC in metastasized neuroendocrine cancers J Clin Oncol 29 2011 2416 2423
45. F. Gigli, A. Gardellini, P. Bertazzoni, G. Martinelli Secondary haematological malignancies after radioimmunotherapy Ann Hematol 91 2012 969
46. E.J. Rolleman, M. Melis, R. Valkema, O.C. Boerman, E.P. Krenning, M. de Jong Kidney protection during peptide receptor radionuclide therapy with somatostatin analogues Eur J Nucl Med Mol Imaging 37 2010 1018 1031
47. K. Oberg The action of interferon alpha on human carcinoid tumours Semin Cancer Biol 3 1992 35 41
48. L.C. Platanias Mechanisms of type-I- and type-II-interferon-mediated signalling Nat Rev Immunol 5 2005 375 386
49. K. Oberg Interferon in the management of neuroendocrine GEP-tumors: a review Digestion 62 Suppl 1 2000 92 97
50. K. Oberg, B. Eriksson The role of interferons in the management of carcinoid tumors Acta Oncol 30 1991 519 522
51. M.E. Pavel, U. Baum, E.G. Hahn, D. Schuppan, T. Lohmann Efficacy and tolerability of pegylated IFN-Alpha in patients with neuroendocrine gastroenteropancreatic carcinomas J Interferon Cytokine Res 26 2006 8 13
52. J.C. Yao, A. Phan, P.M. Hoff Targeting vascular endothelial growth factor in advanced carcinoid tumor: a random assignment phase II study of depot octreotide with bevacizumab and pegylated interferon alpha-2b J Clin Oncol 26 2008 1316 1323
53. K. Öberg Interferon-Alpha versus somatostatin or the combination of both in gastroenteropancreatic tumours Digestion 57 Suppl 1 1996 81 83
54. S. Faiss, U.F. Pape, M. Bohmig Prospective, randomized, multicenter trial on the antiproliferative effect of lanreotide, interferon alfa, and their combination for therapy of metastatic neuroendocrine gastroenteropancreatic tumors - the International Lanreotide and Interferon Alfa Study Group J Clin Oncol 21 2003 2689 2696
55. R. Arnold, A. Rinke, K.J. Klose Octreotide versus octreotide plus interferon-Alpha in endocrine gastroenteropancreatic tumors: a randomized trial Clin Gastroenterol Hepatol 3 2005 761 771
56. E.T. Janson, K. Oberg Randomized clinical trial of the effect of interferon alpha on survival in patients with disseminated midgut carcinoid tumours Br J Surg 90 2003 687 693
57. M. Frank, K.J. Klose, M. Wied, N. Ishaque, C. Schade-Brittinger, R. Arnold Combination therapy with octreotide and alpha-interferon: effect on tumor growth in metastatic endocrine gastroenteropancreatic tumors Am J Gastroenterol 94 1999 1381 1387
58. E.T. Janson, K. Oberg Long-term management of the carcinoid syndrome Treatment with octreotide alone and in combination with alpha-interferon Acta Oncol 32 1993 225 229
59. L. Dahan, F. Bonnetain, P. Rougier Phase III trial of chemotherapy using 5-fluorouracil and streptozotocin compared with interferon alpha for advanced carcinoid tumors: FNCLCC-FFCD 9710 Endocr Relat Cancer 16 2009 1351 1361
60. D. Granberg, B. Eriksson, E. Wilander Experience in treatment of metastatic pulmonary carcinoid tumors Ann Oncol 12 2001 1383 1391
61. I. Duran, J. Kortmansky, D. Singh A phase II clinical and pharmacodynamic study of temsirolimus in advanced neuroendocrine carcinomas Br J Cancer 95 2006 1148 1154
62. J.C. Yao, A.T. Phan, D.Z. Chang Efficacy of RAD001 (everolimus) and octreotide LAR in advanced low- to intermediate-grade neuroendocrine tumors: results of a phase II study J Clin Oncol 26 2008 4311 4318
63. J. Yao, J.D. Hainsworth, E.M. Wolin Multivariate analysis including biomarkers in the phase III RADIANT-2 study of octreotide LAR plus everolimus (E+O) or placebo (P+O) among patients with advanced neuroendocrine tumors (NET) J Clin Oncol 30 Suppl 4 2012 abstract 157
64. A. Kasajima, M. Pavel, S. Darb-Esfahani mTOR expression and activity patterns in gastroenteropancreatic neuroendocrine tumours Endocr Relat Cancer 18 2011 181 192
65. T. Shida, T. Kishimoto, M. Furuya Expression of an activated mammalian target of rapamycin (mTOR) in gastroenteropancreatic neuroendocrine tumors Cancer Chemother Pharmacol 65 2010 889 893
66. A. Couvelard, D. O'Toole, H. Turley Microvascular density and hypoxia-inducible factor pathway in pancreatic endocrine tumours: negative correlation of microvascular density and VEGF expression with tumour progression Br J Cancer 92 2005 94 101
67. S. Faivre, G. Demetri, W. Sargent, E. Raymond Molecular basis for sunitinib efficacy and future clinical development Nat Rev Drug Discov 6 2007 734 745
68. M.E. Pavel, C. Bartel, F. Heuck Open-label, non-randomized, multicenter phase II study evaluating the angiogenesis inhibitor PTK787/ZK222584 (PTK/ZK) in patients with advanced neuroendocrine carcinomas (NEC) Proc Am Soc Clin Oncol 26 2008 abstract 2684
69. K.A. Varker, J. Campbell, M.H. Shah Phase II study of thalidomide in patients with metastatic carcinoid and islet cell tumors Cancer Chemother Pharmacol 61 2008 661 668
70. M.H. Kulke, E.K. Bergsland, D.P. Ryan Phase II study of recombinant human endostatin in patients with advanced neuroendocrine tumors J Clin Oncol 24 2006 3555 3561
71. J.A. Chan, K. Stuart, C.C. Earle Prospective study of bevacizumab plus temozolomide in patients with advanced neuroendocrine tumors J Clin Oncol 9 2012 9
72. M.H. Kulke, J.A. Chan, J.A. Meyerhardt A prospective phase II study of 2-methoxyestradiol administered in combination with bevacizumab in patients with metastatic carcinoid tumors Cancer Chemother Pharmacol 68 2011 293 300
73. P. Kunz, T. Kuo, J. Zahn A phase II study of capecitabine, oxaliplatin, and bevacizumab for metastatic or unresectable neuroendocrine tumors J Clin Oncol 28 Suppl 15S 2010 abstract 4104
74. J. Yao, A.T. Phan, D. Fogleman Randomized run-in study of bevacizumab (B) and everolimus (E) in low- to intermediate-grade neuroendocrine tumors (LGNETs) using perfusion CT as functional biomarker J Clin Oncol 28 15S 2010 abstract 4002
75. M.H. Kulke, H.J. Lenz, N.J. Meropol Activity of sunitinib in patients with advanced neuroendocrine tumors J Clin Oncol 26 2008 3403 3410
76. T. Hobday, J. Rubi, K. Holen MCO44h, a phase II trial of sorafenib in patients with metastatic neuroendocrine tumours (NET): a phase II consortium (P2C) study J Clin Oncol 25 Suppl 18S 2007 abstract 4504
77. D.E. Castellano, J. Capdevila, R. Salazar Sorafenib and bevacizumab combination targeted therapy in advanced neuroendocrine tumor: a phase II study of the Spanish Neuroendocrine Tumor Group (GETNE0801) J Clin Oncol 29 Suppl 2011 abstract 4113
78. C.G. Moertel, J.A. Hanley Combination chemotherapy trials in metastatic carcinoid tumor and the malignant carcinoid syndrome Cancer Clin Trials 2 1979 327 334
79. C.G. Moertel, J. Rubin, M.J. O'Connell Phase II study of cisplatin therapy in patients with metastatic carcinoid tumor and the malignant carcinoid syndrome Cancer Treat Rep 70 1986 1459 1460
80. C.G. Moertel, C.M. Johnson, M.A. McKusick The management of patients with advanced carcinoid tumors and islet cell carcinomas Ann Intern Med 120 1994 302 309
81. W. Sun, S. Lipsitz, P. Catalano, J.A. Mailliard, D.G. Haller Phase II/III study of doxorubicin with fluorouracil compared with streptozocin with fluorouracil or dacarbazine in the treatment of advanced carcinoid tumors: Eastern Cooperative Oncology Group Study E1281 J Clin Oncol 23 2005 4897 4904
82. N.C. Turner, S.J. Strauss, D. Sarker Chemotherapy with 5-fluorouracil, cisplatin and streptozocin for neuroendocrine tumours Br J Cancer 102 2010 1106 1112
83. C.G. Moertel, L.K. Kvols, M.J. O'Connell, J. Rubin Treatment of neuroendocrine carcinomas with combined etoposide and cisplatin Evidence of major therapeutic activity in the anaplastic variants of these neoplasms Cancer 68 1991 227 232
84. M.H. Kulke, B. Wu, D.P. Ryan A phase II trial of irinotecan and cisplatin in patients with metastatic neuroendocrine tumors Dig Dis Sci 51 2006 1033 1038
85. P.F. Engstrom, P.T. Lavin, C.G. Moertel, E. Folsch, H.O. Douglass Jr Streptozocin plus fluorouracil versus doxorubicin therapy for metastatic carcinoid tumor J Clin Oncol 2 1984 1255 1259
86. O. Hentic, A. Couvelard, V. Rebours Ki-67 index, tumor differentiation, and extent of liver involvement are independent prognostic factors in patients with liver metastases of digestive endocrine carcinomas Endocr Relat Cancer 18 2010 51 59
87. P. Corrie, M. Caplin, N. Reed Treatment of advanced neuroendocrine tumors: results of the UKINETS and NCRI randomized phase II NET01 trial J Clin Oncol 30 Suppl 2012 abstract 4121
88. M.P. Brizzi, A. Berruti, A. Ferrero Continuous 5-fluorouracil infusion plus long acting octreotide in advanced well-differentiated neuroendocrine carcinomas A phase II trial of the Piemonte Oncology Network BMC Cancer 9 2009 388
89. U. Ritzel, U. Leonhardt, F. Stockmann, G. Ramadori Treatment of metastasized midgut carcinoids with dacarbazine Am J Gastroenterol 90 1995 627 631
90. S. Ollivier, M. Fonck, Y. Becouarn, R. Brunet Dacarbazine, fluorouracil, and leucovorin in patients with advanced neuroendocrine tumors: a phase II trial Am J Clin Oncol 21 1998 237 240
91. M. Di Bartolomeo, E. Bajetta, A.M. Bochicchio A phase II trial of dacarbazine, fluorouracil and epirubicin in patients with neuroendocrine tumours Ann Oncol 6 1995 77 79
92. E. Bajetta, L. Rimassa, C. Carnaghi 5-Fluorouracil, dacarbazine, and epirubicin in the treatment of patients with neuroendocrine tumors Cancer 83 1998 372 378
93. J.R. Strosberg, R.L. Fine, J. Choi First-line chemotherapy with capecitabine and temozolomide in patients with metastatic pancreatic endocrine carcinomas Cancer 117 2011 268 275
94. S. Ekeblad, A. Sundin, E.T. Janson Temozolomide as monotherapy is effective in treatment of advanced malignant neuroendocrine tumors Clin Cancer Res 13 2007 2986 2991
95. F. Maire, P. Hammel, S. Faivre Temozolomide: a safe and effective treatment for malignant digestive endocrine tumors Neuroendocrinology 90 2009 67 72
96. M.H. Kulke, J.L. Hornick, C. Frauenhoffer O6-methylguanine DNA methyltransferase deficiency and response to temozolomide-based therapy in patients with neuroendocrine tumors Clin Cancer Res 15 2009 338 345
97. E. Bajetta, L. Catena, G. Procopio Are capecitabine and oxaliplatin (XELOX) suitable treatments for progressing low-grade and high-grade neuroendocrine tumours? Cancer Chemother Pharmacol 59 2007 637 642
98. I. Akunyili, M.T. Garcia-Buitrago, J. Macintyre, J. Levi, C.M. Rocha Lima Sustained response to FOLFOX and bevacizumab in metastatic bronchial carcinoid - a case report and review of the literature J Gastrointest Oncol 2 2011 117 121
99. P.A. Cassier, T. Walter, B. Eymard Gemcitabine and oxaliplatin combination chemotherapy for metastatic well-differentiated neuroendocrine carcinomas: a single-center experience Cancer 115 2009 3392 3399
100. U. Pape, N. Tiling, C. Bartel, U. Plöckinger, B. Wiedenmann Oxaliplatin plus 5-fluorouracil/folinic acid as palliative treatment for progressive malignant gastrointestinal neuroendocrine carcinomas J Clin Oncol 24 18S 2006 abstract 14074
101. A.P. Venook, A.H. Ko, M.A. Tempero Phase II trial of FOLFOX plus bevacizumab in advanced, progressive neuroendocrine tumors J Clin Oncol 26 Suppl 2008 abstract 15545
102. A. Srivastava, J.L. Hornick Immunohistochemical staining for CDX-2, PDX-1, NESP-55, and TTF-1 can help distinguish gastrointestinal carcinoid tumors from pancreatic endocrine and pulmonary carcinoid tumors Am J Surg Pathol 33 2009 626 632
103. G. Hermann, B. Konukiewitz, A. Schmitt, A. Perren, G. Kloppel Hormonally defined pancreatic and duodenal neuroendocrine tumors differ in their transcription factor signatures: expression of ISL1, PDX1, NGN3, and CDX2 Virchows Arch 459 2011 147 154
104. V. Prasad, V. Ambrosini, M. Hommann, D. Hoersch, S. Fanti, R.P. Baum Detection of unknown primary neuroendocrine tumours (CUP-NET) using (68)Ga-DOTA-NOC receptor PET/CT Eur J Nucl Med Mol Imaging 37 2010 67 77
105. 68Ga- DOTATOC-PET/CT on therapy management in patients with neuroendocrine tumors Neuroendocrinology 91 2010 101 109
106. H. Jann, S. Roll, A. Couvelard Neuroendocrine tumors of midgut and hindgut origin: tumor-node-metastasis classification determines clinical outcome Cancer 117 2011 3332 3341
107. S. Niraula, B. Seruga, A. Ocana The price we pay for progress: a meta-Analysis of harms of newly approved anticancer drugs J Clin Oncol 30 2012 3012 3019